CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
Adoptive cell therapy with chimeric antigen receptor (CAR) immunotherapy has made
tremendous progress with five CAR T therapies approved by the US Food and Drug …
tremendous progress with five CAR T therapies approved by the US Food and Drug …
Cytotoxic CD4+ T cells in cancer: expanding the immune effector toolbox
DY Oh, L Fong - Immunity, 2021 - cell.com
Cytotoxic T cells are important effectors of anti-tumor immunity. While tumor killing is
ascribed to CD8+ T cell function, pre-clinical and clinical studies have identified intra …
ascribed to CD8+ T cell function, pre-clinical and clinical studies have identified intra …
CAR-T cell therapy: current limitations and potential strategies
RC Sterner, RM Sterner - Blood cancer journal, 2021 - nature.com
Chimeric antigen receptor (CAR)-T cell therapy is a revolutionary new pillar in cancer
treatment. Although treatment with CAR-T cells has produced remarkable clinical responses …
treatment. Although treatment with CAR-T cells has produced remarkable clinical responses …
Recent advances and discoveries in the mechanisms and functions of CAR T cells
This Review discusses the major advances and changes made over the past 3 years to our
understanding of chimeric antigen receptor (CAR) T cell efficacy and safety. Recently, the …
understanding of chimeric antigen receptor (CAR) T cell efficacy and safety. Recently, the …
The journey of CAR-T therapy in hematological malignancies
J Lu, G Jiang - Molecular cancer, 2022 - Springer
Chimeric antigen receptor T (CAR-T) cells therapy has revolutionized the treatment
paradigms for hematological malignancies, with multi-line therapy-refractory patients …
paradigms for hematological malignancies, with multi-line therapy-refractory patients …
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
S Rafiq, CS Hackett, RJ Brentjens - Nature reviews Clinical oncology, 2020 - nature.com
T cells genetically engineered to express chimeric antigen receptors (CARs) have proven—
and impressive—therapeutic activity in patients with certain subtypes of B cell leukaemia or …
and impressive—therapeutic activity in patients with certain subtypes of B cell leukaemia or …
Recent advances in CAR-T cell engineering
R Huang, X Li, Y He, W Zhu, L Gao, Y Liu… - Journal of hematology & …, 2020 - Springer
Chimeric antigen receptor T (CAR-T) cell therapy is regarded as an effective solution for
relapsed or refractory tumors, particularly for hematological malignancies. Although the …
relapsed or refractory tumors, particularly for hematological malignancies. Although the …
Human chimeric antigen receptor macrophages for cancer immunotherapy
M Klichinsky, M Ruella, O Shestova, XM Lu… - Nature …, 2020 - nature.com
Chimeric antigen receptor (CAR) T cell therapy has shown promise in hematologic
malignancies, but its application to solid tumors has been challenging,,–. Given the unique …
malignancies, but its application to solid tumors has been challenging,,–. Given the unique …
CAR T cell therapy for solid tumors: bright future or dark reality?
Chimeric antigen receptor (CAR) T cell therapy has garnered significant excitement due to
its success for hematological malignancies in clinical studies leading to the US Food and …
its success for hematological malignancies in clinical studies leading to the US Food and …
Killing mechanisms of chimeric antigen receptor (CAR) T cells
Effective adoptive T cell therapy (ACT) comprises the killing of cancer cells through the
therapeutic use of transferred T cells. One of the main ACT approaches is chimeric antigen …
therapeutic use of transferred T cells. One of the main ACT approaches is chimeric antigen …